On February 6, 2018 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in two upcoming investor conferences (Press release, MacroGenics, FEB 6, 2018, View Source [SID1234523762]). These two conferences include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SunTrust Robinson Humphrey 2018 Orphan Drug Day — Management will participate in the conference on Tuesday, February 13, 2018, at the JW Marriott Essex House in New York.

Leerink Partners 7th Annual Global Healthcare Conference — Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, February 15, 2018 at 10:30 am ET at the Lotte New York Palace in New York.

A webcast of the Leerink conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.